Effects of dasiglucagon injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Effects of dasiglucagon injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dasiglucagon injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dasiglucagon injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Dasiglucagon, a next-generation glucagon analog, has been shown to be effective and safe for the treatment of severe hypoglycemia in children, adolescents, and adults with type 1 diabetes. 3 , 1 , 2

Dasiglucagon consistently increases plasma glucose levels in people with type 1 diabetes mellitus, both in hypoglycemic and euglycemic conditions. 9

Dasiglucagon has also been shown to be effective in mitigating postbariatric postprandial hypoglycemia in individuals who have undergone Roux-en-Y gastric bypass (RYGB) surgery. 8

Dasiglucagon is available as a single-dose autoinjector or prefilled syringe for subcutaneous injection, making it easy for patients to use at home. 5 , 1

Low-dose dasiglucagon has shown potential for preventing insulin-induced hypoglycemia in people with type 1 diabetes. 10

Benefits and risks

Benefit summary

Dasiglucagon offers several important advantages as a rapid and effective treatment for severe hypoglycemia in patients with type 1 diabetes. Dasiglucagon has been shown to raise blood glucose levels more quickly and effectively compared to traditional glucagon formulations. Moreover, it is available in both self-injecting devices and prefilled syringes, allowing for easy administration at home. These benefits enable patients to receive rapid and effective treatment in case of severe hypoglycemia.

Risk summary

While generally safe, dasiglucagon may cause some side effects. The most common ones include nausea, vomiting, and abdominal pain. Dasiglucagon may interact with certain medications. Therefore, it is essential to inform your doctor about all medical conditions and medications before using dasiglucagon.

Comparison of studies

Commonalities of studies

These studies demonstrate that dasiglucagon is an effective and safe medication for treating severe hypoglycemia in patients with type 1 diabetes. All these studies indicate that dasiglucagon raises blood glucose levels more quickly and effectively compared to traditional glucagon formulations.

Differences of studies

These studies differ in terms of the administration method of dasiglucagon, the study populations, and the endpoints evaluated. While some studies administered dasiglucagon using self-injecting devices or prefilled syringes, others used intravenous administration. Some studies focused on patients experiencing severe hypoglycemia, while others evaluated the preventive effect against hypoglycemia. These differences can make direct comparison of results between studies challenging.

Consistency and discrepancies of results

Most of these studies suggest that dasiglucagon is an effective and safe medication for treating severe hypoglycemia in patients with type 1 diabetes. The results of these studies are consistent and support the effectiveness and safety of dasiglucagon. However, these studies have some differences regarding the administration method of dasiglucagon, the study populations, and the endpoints evaluated. Therefore, it is challenging to directly compare the results of these studies. Future research is necessary to conduct larger studies and evaluate the effectiveness and safety of dasiglucagon in various populations and scenarios.

Considerations for practical application

Dasiglucagon can provide a rapid and effective treatment when patients with type 1 diabetes experience severe hypoglycemia. However, dasiglucagon is not a substitute for preventing severe hypoglycemia. Patients with type 1 diabetes need to carefully manage their blood glucose levels and follow their doctor's instructions to minimize the risk of severe hypoglycemia. While dasiglucagon can raise blood glucose levels more quickly and effectively than traditional glucagon formulations, it might also have a higher risk of side effects compared to traditional glucagon. It is crucial to inform your doctor about all medical conditions and medications before using dasiglucagon.

Limitations of current research

While these studies demonstrate that dasiglucagon is an effective and safe medication for treating severe hypoglycemia in patients with type 1 diabetes, they have certain limitations. These studies were relatively small and focused on specific populations. Therefore, their results might not be generalizable to other populations. Additionally, these studies compared dasiglucagon to traditional glucagon formulations, but there are limited studies comparing dasiglucagon to other hypoglycemia treatments. Further research is needed to conduct larger studies and evaluate the effectiveness and safety of dasiglucagon in various populations and scenarios.

Directions for future research

Further research on dasiglucagon is needed. Future studies should focus on comparing dasiglucagon to other hypoglycemia treatments, evaluating the long-term effectiveness and safety of dasiglucagon, and optimizing the administration method of dasiglucagon.

Conclusion

Multiple clinical trials have shown that dasiglucagon is an effective and safe medication for treating severe hypoglycemia in patients with type 1 diabetes. Dasiglucagon has been shown to raise blood glucose levels more quickly and effectively compared to traditional glucagon formulations. Moreover, it is available in both self-injecting devices and prefilled syringes, allowing for easy administration at home. These benefits enable patients to receive rapid and effective treatment in case of severe hypoglycemia. However, dasiglucagon is not a substitute for preventing severe hypoglycemia. Patients with type 1 diabetes need to carefully manage their blood glucose levels and follow their doctor's instructions to minimize the risk of severe hypoglycemia.

Message to readers: It is crucial for patients with type 1 diabetes to understand the risk of severe hypoglycemia and consult their doctors to ensure they can receive appropriate treatment if needed.

Literature analysis of 10 papers
Positive Content
10
Neutral Content
0
Negative Content
0
Article Type
7
0
0
3
10
1.

Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.

Author: BaileyTimothy S, WillardJulie, KlaffLeslie J, Yager StoneJenine, MelgaardAnita, TehranchiRamin

Rapid reversal of hypoglycemia
Reliable treatment for hypoglycemia
Well tolerated
Nausea
Vomiting

Dasiglucagon, administered via an autoinjector device, rapidly reversed hypoglycemia in adults with type 1 diabetes, with a median recovery time of 10 minutes. The treatment was well tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.

Author: PieberThomas R, AronsonRonnie, HövelmannUlrike, WillardJulie, Plum-MörschelLeona, KnudsenKim M, BandakBenedikte, TehranchiRamin

Convenient formulation
Improved safety and tolerability
Rapid hypoglycemia reversal
Nausea and vomiting

Dasiglucagon, a ready-to-use glucagon analog, provided rapid and effective reversal of hypoglycemia in adults with type 1 diabetes, with safety and tolerability similar to reconstituted glucagon injection.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.

Author: BattelinoTadej, TehranchiRamin, BaileyTimothy, DovcKlemen, MelgaardAnita, Yager StoneJenine, WoernerStephanie, von dem BergeThekla, DiMeglioLinda, DanneThomas

Dasiglucagon efficacy
Hypoglycemia treatment
Nausea
Vomiting

Dasiglucagon, a ready-to-use glucagon analog formulation, was evaluated for its safety and efficacy in treating severe hypoglycemia in 42 children and adolescents with type 1 diabetes. Dasiglucagon rapidly and effectively restored plasma glucose levels compared to placebo, with an overall safety profile similar to glucagon.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

4.

Dasiglucagon: an effective medicine for severe hypoglycemia.

Author: XuBo, TangGaorui, ChenZhen

Treat hypoglycemia

This review article discusses the basic properties and clinical effects of dasiglucagon, a stable glucagon analog approved for the treatment of severe hypoglycemia in patients with type 1 diabetes mellitus.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Dasiglucagon: First Approval.

Author: BlairHannah A

Congenital hyperinsulinism treatment
T1DM management
Treatment of hypoglycemia

This article summarizes the milestones in the development of dasiglucagon, a glucagon analogue, leading to its approval for the treatment of severe hypoglycemia in patients with diabetes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Author: HövelmannUlrike, BystedBritta Væver, MouritzenUlrik, MacchiFrancesca, LamersDaniela, KronshageBirgit, MøllerDaniél Vega, HeiseTim

hypoglycemia treatment

This study compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety and tolerability of dasiglucagon, a novel soluble glucagon analog, with GlucaGen in insulin-induced hypoglycemia. The study found that dasiglucagon was effective in treating hypoglycemia and had a favorable safety profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.

Author: La SalaLucia, PontiroliAntonio E

Fast-acting glucagon diabetes

This article discusses the role of fast-acting glucagon in the treatment of severe hypoglycemia in insulin-treated patients with diabetes. The article highlights the benefits of nasal glucagon and injectable glucagon solutions over traditional glucagon injections.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.

Author: NielsenCasper K, ØhrstrømCaroline C, KielgastUrd L, HansenDorte L, HartmannBolette, HolstJens J, LundAsger, VilsbøllTina, KnopFilip K

Reduced postprandial hypoglycemia

This study found that dasiglucagon, a novel stable glucagon analog, effectively mitigated postprandial hypoglycemia in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.

Author: HövelmannUlrike, OlsenMinna Braendholt, MouritzenUlrik, LamersDaniela, KronshageBirgit, HeiseTim

Hypoglycemia treatment
Nausea
Vomiting

Dasiglucagon is a novel glucagon analogue that rapidly increased plasma glucose levels (mean increases 30 minutes post-dosing of 2.2 to 4.4 mmol/L [39-80 mg/dL] from euglycaemia and 1.3 to 5.2 mmol/L [24-94 mg/dL] from hypoglycaemia) in a dose-dependent manner. It is a good candidate for use in dual-hormone artificial pancreas systems.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.

Author: LaugesenChristian, RanjanAjenthen G, SchmidtSigne, NørgaardKirsten

Hypoglycemia prevention
Nausea

A randomized crossover study of 20 adults with type 1 diabetes found that low-dose subcutaneous dasiglucagon was safe and effective in preventing insulin-induced hypoglycemia with a faster glucose-elevating profile than oral glucose.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.